efgartigimod gMG
Selected indexed studies
- Subcutaneous efgartigimod PH20 in generalized myasthenia gravis: A phase 3 randomized noninferiority study (ADAPT-SC) and interim analyses of a long-term open-label extension study (ADAPT-SC+). (Neurotherapeutics, 2024) [PMID:39227284]
- Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+): interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravis. (Front Neurol, 2023) [PMID:38318236]
- Efgartigimod for generalized myasthenia gravis: A multicenter real-world cohort study in China. (Ann Clin Transl Neurol, 2024) [PMID:38973109]
_Worker-drafted node — pending editorial review._
Connections
efgartigimod gMG is a side effect of
Sources
- A real-life experience with eculizumab and efgartigimod in generalized myasthenia gravis patients. (2024) pubmed
- Subcutaneous efgartigimod PH20 in generalized myasthenia gravis: A phase 3 randomized noninferiority study (ADAPT-SC) and interim analyses of a long-term open-label extension study (ADAPT-SC+). (2024) pubmed
- Long-term safety, tolerability, and efficacy of efgartigimod (ADAPT+): interim results from a phase 3 open-label extension study in participants with generalized myasthenia gravis. (2023) pubmed
- Efgartigimod for generalized myasthenia gravis: A multicenter real-world cohort study in China. (2024) pubmed
- ADAPT NXT: Fixed Cycles or Every-Other-Week IV Efgartigimod in Generalized Myasthenia Gravis. (2025) pubmed
- Real-World experience with efgartigimod in patients with myasthenia gravis. (2024) pubmed
- Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis. (2019) pubmed
- Efgartigimod: A Review in Generalised Myasthenia Gravis. (2024) pubmed
- Safety profile of efgartigimod from global clinical trials across multiple immunoglobulin G-mediated autoimmune diseases. (2025) pubmed
- Efgartigimod and Ravulizumab for Treating Acetylcholine Receptor Auto-antibody-Positive (AChR-Ab+) Generalized Myasthenia Gravis: Indirect Treatment Comparison. (2024) pubmed